Artificial Intelligence In Precision Medicine Market To Witness the Highest Growth Globally in Coming Years 2020-2026 – Cole of Duty

Posted on by

The Global Artificial Intelligence In Precision Medicine Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2026. The Artificial Intelligence In Precision Medicine Market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Artificial Intelligence In Precision Medicine Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

The global Artificial Intelligence In Precision Medicine market was valued at $719 million in 2017 and is estimated to reach $18,119 million at a CAGR of 49.6% from 2018 to 2025.

Top Companies: Intel AI, IBM, GE Healthcare, Thermo Fisher Scientific, Qiagen, Berg Health, Medasense Biometrics,

Get a sample copy Of this Report:

https://www.marketinsightsreports.com/reports/06172095179/covid-19-impact-on-global-artificial-intelligence-in-precision-medicine-market-size-status-and-forecast-2020-2026/inquiry?Mode=31

Overview: Artificial intelligence (AI) in medicine is used to analyze complex medical data by approximating human cognition with the help of algorithms and software. The development of novel pharmaceuticals and biologicals through clinical trials can take more than a decade and cost billions of dollars during that tenure period. AI technology can help to make this process faster and cheaper, which in turn is expected to help improve the efficiency of pharmaceutical and biotechnology companies.

Global Artificial Intelligence In Precision Medicine Market Split By Product Type And Applications:

This report segments the global Artificial Intelligence In Precision Medicine Market on the basis ofTypesare:

HardwareSoftwareServices

On the basis ofApplication, the Global Artificial Intelligence In Precision Medicine Market is segmented into:

OncologyNeurosciencesImmunologyRespiratoryOthers

Regional Analysis: For a comprehensive understanding of market dynamics, the global Artificial Intelligence In Precision Medicine Market is analyzed across key geographies namely: United States, China, Europe, Japan, Middle East & Africa, India, and others. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Explore Full Report With Detailed TOC Here:

https://www.marketinsightsreports.com/reports/06172095179/covid-19-impact-on-global-artificial-intelligence-in-precision-medicine-market-size-status-and-forecast-2020-2026?Mode=31

Influence of the Artificial Intelligence In Precision Medicine Market report:-Comprehensive assessment of all opportunities and risks in the Artificial Intelligence In Precision Medicine Market. Artificial Intelligence In Precision Medicine Market recent innovations and major events.-A detailed study of business strategies for the growth of the Artificial Intelligence In Precision Medicine Market-leading players.-Conclusive study about the growth plot of the Artificial Intelligence In Precision Medicine market for forthcoming years.-In-depth understanding of Artificial Intelligence In Precision Medicine Market -particular drivers, constraints, and major micro markets.-Favorable impression inside vital technological and market latest trends striking the Artificial Intelligence In Precision Medicine Market.

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Artificial Intelligence In Precision Medicine Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Finally, The Artificial Intelligence In Precision Medicine Market report is the believable source for gaining Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and Market development rate and figure, and so on. This report additionally Present a new task SWOT examination, speculation attainability investigation, and venture return investigation.

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected]|[emailprotected]

See the original post:

Artificial Intelligence In Precision Medicine Market To Witness the Highest Growth Globally in Coming Years 2020-2026 - Cole of Duty

Online game looks to stoke interest in regenerative medicine – The Union Leader

Posted on by

An online game that lets students learn about stem cells and tissue engineering also offered them information about high school and college internship programs to further spur their interest in regenerative medicine.

Through the game, aimed mainly at seventh graders through high school seniors, students competed in daily challenges to win swag and the chance to meet inventor Dean Kamen (virtually in this pandemic age).

The vision is to help inform young people about all the really cool things that are happening in this space, said Alexander Titus, the freshly minted chief strategy officer at the Advanced Regenerative Manufacturing Institute in Manchesters Millyard.

The game helps to inspire students as they choose their classes, their elective classes in high school and particularly majors in college, Titus said last week.

Nearly 100 students took part in the game, which ended Friday. The content about regenerative medicine will remain online through June.

ARMI, which is working to manufacture human tissue commercially, is working on recruiting tomorrows workforce one cool video at a time.

I think the timing of this couldnt be any better, said Julie Demers, executive director of the New Hampshire Tech Alliance. The pandemic has limited in-person, work-based learning opportunities and interactions with industry professionals. Interactive opportunities to get students interested in and thinking about career opportunities are critical.

Titus said a chief goal is to build a pipeline of future workers.

Its all tied together in attracting students while theyre young to understand the process of what to study along the way to get to college and a job when theyre done, said Titus, who earned a Ph.D. in quantitative biomedical sciences at Dartmouth.

Titus said he expects the game to help ARMI officials learn what draws the interest of students so they can develop other programming they know will garner student interest, he said.

The ARMI challenge, called TEMPtation, featured profiles of businesses from more than a dozen states as well as universities and colleges interested in regenerative medicine.

Arizona State University holds summer camps for middle and high school students that are interested in learning more about science and mathematics, read one profile.

From Georgia Tech in Atlanta: Georgia Tech has a Center for Career Discovery & Development, which offers internships, co-ops, and career services that give students the resources they need to support their search for employment following their graduation.

Formerly employed at the U.S. Department of Defense, Titus returned to New Hampshire to join ARMI.

The mission, he said, is marrying science and manufacturing.

Bring the science to the stage where we can automate it and market the new technologies we couldnt make before, said Titus, previously assistant director for biotechnology within the Office of the Under Secretary of Defense for Research & Engineering.

ARMI features more than 150 partners and more than $300 million in government and private investment committed.

If we want to be able to produce a replacement heart for people who have heart disease, what are the components that go into that? Titus said.

He hopes ARMI can attract startups in the Manchester area, allowing for ARMI to mentor them until they are viable companies.

The idea is for companies to move into New Hampshire and move into our ecosystem if you will, Titus said.

I think especially given now, where were seeing so many people in the cities during COVID have a hard time social distancing, I expect well see some shifting of people out of the cities, said Titus, who speculated some could settle in New Hampshire.

Whats Working, a series exploring solutions for New Hampshires workforce needs, is sponsored by the New Hampshire Solutions Journalism Lab at the Nackey S. Loeb School of Communications and is funded by Eversource, the New Hampshire Charitable Foundation, Dartmouth-Hitchcock Medical Center, the New Hampshire College & University Council, Northeast Delta Dental and the New Hampshire Coalition for Business and Education. Contact reporter Michael Cousineau at mcousineau@unionleader.com. To read stories in the series, visit unionleader.com/whatsworking.

Read the rest here:

Online game looks to stoke interest in regenerative medicine - The Union Leader

Covid 19 Analysis On Regenerative Medicine Market: Comprehensive Study Explores Huge Growth of 2024 with Top Key Players Depuy Synthes, Inc.,…

Posted on by

CMI presents an in-depth overview of the Global Regenerative Medicine Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are Depuy Synthes, Inc., Orthofix, Inc., NuVasive, Inc. and Zimmer Holdings, Inc..

This study focuses on the Global Regenerative Medicine market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Regenerative Medicine growth in Key regions. In order to provide valuable insight by each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

You Keep Your Social Distance And We Provide You A Social DISCOUNT Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On All CMI Reports.

We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Request A Sample Copy Regenerative Medicine Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/163

The Global Regenerative Medicine is segmented by:

By Product Type: Global Regenerative Medicine Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned: Depuy Synthes, Inc., Orthofix, Inc., NuVasive, Inc. and Zimmer Holdings, Inc.

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report includes Depuy Synthes, Inc., Orthofix, Inc., NuVasive, Inc. and Zimmer Holdings, Inc.. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Enquire here get customization & check discount, please click: https://www.coherentmarketinsights.com/insight/request-discount/163

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Regenerative Medicine Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Analysis of M&As, Partnership & JVs in Global Regenerative Medicine Industry in the United States & Other Emerging Geographies

Top 10 Global Regenerative Medicine Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Regenerative Medicine MARKET LANDSCAPE

Market EntropyMarket segmentation analysisMarket characteristics

PART 06: Global Regenerative Medicine MARKET SIZING

Market definitionMarket size and forecastMarket sizing

PART 07: Global Regenerative Medicine MARKET SEGMENTATION

SegmentationMarket opportunityComparison

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Follow this link:

Covid 19 Analysis On Regenerative Medicine Market: Comprehensive Study Explores Huge Growth of 2024 with Top Key Players Depuy Synthes, Inc.,...

Does a ‘Married to Medicine’ Cast Member Have a Net Worth of $500 Million? – Showbiz Cheat Sheet

Posted on by

Every Married to Medicine cast member is a millionaire but does the newest addition really have a net worth of $500 million? Maybe at least she compared herself to someone with that fortune.

Buffie Purselleis married to a physician but has created her own empire as a personal finance and tax expert. She shared on CNBC in 2017 she built her net worth through a number of businesses shes created. She admits to working up to 12 hours a day and only sleeps a total of 40 hours per week.

Known as Buffie the Tax Heiress Purselle said, Im going to quote Beyonce when she said that she thinks she might be the black Bill Gates. I think I just might be the black, curvy, fabulous Marcus Lemonis-in-the-making. Marcus Lemonis has a net worth of $500 million. Shes undoubtedly a resourceful and powerful entrepreneur. However, other resources put Purselles net worth closer to $1 million.

Toya Bush-Harris and Dr. Heavenly Kimes both have a reported net worth of $4 million each. Kimes runs a successful dental practice in Atlanta who specializes in cosmetic dentistry. She often shares success stories on Instagram and patient transformation photos. Replacing missing teeth can restore your smile to optimal health, function and appearance. Dental implants are a great option for restoring your smile because the implants are designed to look, function and feel just like your natural teeth, and with proper care, they can last a lifetime, she recently shared along with a video.

RELATED: This Is How Much the Stars of Married to Medicine Make in Real Life

Bush-Harris is married to a physician and is a published author. She released the childrens book, SleepyHead Please Go To Bed!Bush-Harris created a tremendous social media following using the hashtag, #MommyChronicles.

Also worth $4 million is Mariah Huq who is a Married to Medicine creator and producer. Huq is married to Dr. Aydin Huq and she often entertains at her lavish home on the series.

Married to Medicine top docs all have a net worth ranging from $3.5 to $3 million. Dr. Simone Whitmore has a net worth of $3.5 million as one of the most sought after OB/GYNs in the Atlanta area. Whitmore is a mother of two and has been with husband Cecil for 23 years. Viewers witnessed the couple experiencing rocky moments throughout the series.

Dr. Jacqueline Walters has a net worth of $3 million is also a highly respected OB/GYN in Atlanta. Walters is a published author and a two-time breast cancer survivor. She also openly discussed her infertility on the series.

RELATED: After Hesitating To Start a Family With Her Ex-Husband, Married To Medicine Star Quad Webb Has Adopted a Daughter

Also, with a net worth of $3 million is Dr. Contessa Metcalfe. Metcalfe focuses her practice on preventative medicine and became friends with Dr. Britten Cole while in the Navy. Metcalfe became the crossover cast member between Married to Medicine and Married to Medicine Los Angeles.

Quad Webb is a millionaire in her own right. With a reported net worth of $1.5 million, Webb was a medical sales representative when she first joined the series. But now owns Picture Perfect Pup, a specialty brand designed for dogs. She was originally married to Dr. Gregory Lunceford but the couple has since divorced. Webb recently adopted a baby.

Link:

Does a 'Married to Medicine' Cast Member Have a Net Worth of $500 Million? - Showbiz Cheat Sheet

Covid-19 Impact On Bioelectric Medicine Market Report-Impact Of The Virus On Leading Companies In The World. GlaxoSmithKline, Medtronic Plc., Boston…

Posted on by

Bioelectric Medicine Market Report Global analysis report is very helpful in understanding the Bioelectric Medicine market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better. The current market is evolving its presence and some of the major players in the study areGlaxoSmithKline, Medtronic Plc., Boston Scientific Corporation, Liva Nova Plc, Electrocore, Nevro, and St. Jude Medical..

The Bioelectric Medicine Market research study will give the answer to questions about the present performance of the market and the competitive scope, opportunity, challenges, cost, and more. The market can be divided based on product types and its sub-type, key applications, and major regions. Then it discusses recent product innovations and provides a scenario of potential regional market shares. It aims to fulfill your targeted customers understanding, needs, and wants as well as to explain how effectively a company can meet its requirements.

Note: *The Download PDF brochure only consists of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.

Request A PDF Sample Copy Bioelectric Medicine Market Report Click here: https://www.coherentmarketinsights.com/insight/request-pdf/1757

Highlights of the Global Bioelectric Medicine report:

Overall data will help improve clients competitive study, economic decision-making ability, as well as business planning, and the scope of futuristic developments in the global Bioelectric Medicine market. The complex data is explained in a well-structured manner by the experts and for which they used various analytical techniques and represent the data in the form of graphs, flowcharts, and diagrams.

Important Facts About Bioelectric Medicine Market Report:

The Bioelectric Medicine industry report features different approaches and procedures endorsed by the market key players to make vital business decisions.

The keyword market depicts some parameters such as production value, Bioelectric Medicine marketing strategy analysis, Distributors/Traders, and effect factors are also mentioned in this Bioelectric Medicine Market research report.

This research report reveals Bioelectric Medicine market overview, product overview, market share, supply chain analysis, demand and supply ratio, and import/export details.

Key Topics Covered in this Bioelectric Medicine Market Study:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Market EcosystemMarket CharacteristicsMarket Segmentation Analysis

Part 05: Market Sizing

Bioelectric Medicine Market DefinitionMarket SizingMarket Size And Forecast

Part 06: Five Forces Analysis

Bargaining Power of BuyersBargaining Power of SuppliersThe threat of New EntrantsThreat of SubstitutesThreat of RivalryMarket Condition

Part 07: Customer Landscape Part 08: Regional Landscape

Geographical SegmentationRegional ComparisonAmericas Market Size And ForecastEMEA Market Size And ForecastAPAC Market Size And Forecast

Part 09: Decision Framework Part 10: Drivers And Challenges

Market DriversMarket Challenges

Part 11: Market Trends Part 12: Vendor Landscape

OverviewLandscape DisruptionVendors CoveredVendor ClassificationMarket Positioning Of Vendors

Have Any Query? Ask Our Industry Expert @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1757

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

See the article here:

Covid-19 Impact On Bioelectric Medicine Market Report-Impact Of The Virus On Leading Companies In The World. GlaxoSmithKline, Medtronic Plc., Boston...

FDA Provides Approval of Keytruda For Treatment of Mesothelioma and Other Tumors – Mesothelioma.net Blog

Posted on by

Published on June 18, 2020

Following confirmation of positive results, the U.S. Food and Drug Administration has approved the use of the immunotherapy drug pembrolizumab (Keytruda) for patients diagnosed with unresectable or metastatic malignant mesothelioma, as well as other solid tumor cancers.

The approval was specifically provided for patients with mesothelioma tumors and other tumors that contain levels of tissue tumor mutation that are considered high as determined by an FDA-approved test, whose disease has progressed despite having received other treatments and for whom there are no good alternatives available.

In explaining its rationale for approval of the innovative treatment, the FDA issued a press release indicating that clinical trials had shown a response rate of 29% in patients with mesothelioma and other tumors who demonstrated this particular mutation biomarker level. The agency referred to these results as quite impressive, and particularly in light of the challenges presented by these diseases.

The FDA has indicated that the approval of Keytruda for use in mesothelioma is contingent upon verification of clinical benefit in future trials, and reports that the approval is supported by findings from an analysis of 10 cohorts of patients. The results were notably better than what was found in patients whose tumor mutation levels were not categorized as high.

The positive results gathered from the ten cohorts showed complete responses in 4% of patients and partial responses in 25%. More than half of the patients in the study were able to gain a benefit for at least one year, and half of that group had responses of at least two years. Speaking of the approval, Roy S. Herbst, MD, PhD, ensign professor of medicine (medical oncology) and professor of pharmacology, Yale School of Medicine; chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital; and associate cancer center director for translational research, Yale Cancer Center, said, As physicians, we are always looking to find new options for patients, especially in the second-line or higher treatment setting. Its great to see the use of innovative biomarkers and immunotherapy come together with this approval and encouraging that we now have an option for patients with TMB-H tumors across cancer types, including rare cancers.

For mesothelioma patients, news of expanded treatment options approved by the FDA is very encouraging. For information on treatment centers offering state of the art options, contact the Patient Advocates at Mesothelioma.net today at1-800-692-8608.

Learn more about and contact Terri

Originally posted here:

FDA Provides Approval of Keytruda For Treatment of Mesothelioma and Other Tumors - Mesothelioma.net Blog

Study Reveals Weakness of Vide-Assisted Pleural Biopsy for Mesothelioma Diagnosis – Mesothelioma.net Blog

Posted on by

Published on June 17, 2020

When a patient is suspected of having malignant pleural mesothelioma, speed is of the essence. The physicians goal is to confirm the diagnosis as quickly as possible so that they can devise the most effective treatment protocol for the patients specific condition. One of the most frequently-used tools in staging this rare and fatal form of cancer is to take a tissue sample from the tumor via video-assisted thoracospic surgery, or VATS. Though this video-assisted pleural biopsy has long been highly regarded, a new study out of Japan has revealed significant weaknesses in its accuracy.

Though most oncologists will quickly order a video-assisted pleural biopsy when malignant pleural mesothelioma is suspected, oncologists at Hyogo College of Medicine in Japan have recently conducted research on 400 patients suspected of having the aggressive form of asbestos-related cancer, and have found significant vulnerabilities in the accuracy of its results.

Though the cancer doctors found that video-assisted pleural biopsy correctly identified mesothelioma in many patients, those who are in the earliest stages of the disease or whose bodies are reacting with a significant amount of inflammation or growths of fibrous connective tissue around the tumor had a high likelihood of being misdiagnosed. These misdiagnoses can often lead to delays in much-needed treatment.

Though the Japanese researchers did not conclude that video-assisted pleural biopsy should be entirely abandoned when malignant pleural mesothelioma is suspected, they did warn physicians who may order the test that though it is advantageous due to its minimally-invasive approach, there are many situations where it falls short of the specific patients needs.

In the case of this study, of the 400 patients tested for pleural mesothelioma between 2004 and 2017, roughly 70 percent had that diagnosis confirmed by the testing, but ten percent were misdiagnosed. Approximately 102 were diagnosed with either atypical mesothelial proliferation or non-specific pleuritis, and 9.8 percent of those diagnoses were incorrect and later diagnosed as malignant mesothelioma.

If you or someone you love has been exposed to asbestos and begins to show symptoms suggestive of malignant mesothelioma, then getting accurate diagnostic testing is one of the most important steps you can take. For more information on access to crucial medical resources, contact the Patient Advocates at Mesothelioma.net today at1-800-692-8608.

Learn more about and contact Terri

Read more from the original source:

Study Reveals Weakness of Vide-Assisted Pleural Biopsy for Mesothelioma Diagnosis - Mesothelioma.net Blog

Malignant Mesothelioma Market Emerging Trends, Global Demand and Business Opportunities 2020 to 2026 – 3rd Watch News

Posted on by

COVID-19 Impact Analysis of Malignant Mesothelioma Market

[Los Angeles], [United States], June 2020, The Malignant Mesothelioma Market research report includes an in-sight study of the key [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026] market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the Malignant Mesothelioma report to gain a clear view of the competitive landscape and accordingly plan Malignant Mesothelioma market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Malignant Mesothelioma specifications, and company profiles. The Malignant Mesothelioma study is segmented by Module Type, Test Type, And Region.

The market size section gives the Malignant Mesothelioma market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Malignant Mesothelioma industry over a defined period.

Download Full PDF Sample Copy of Report: https://www.qyresearch.com/sample-form/form/1531346/global-malignant-mesothelioma-market

Key Manufacturers of Malignant Mesothelioma Market include: AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma

The research covers the current market size of the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026]and its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc.,. The in-depth information by segments of Malignant Mesotheliomamarket helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026].

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026]. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Read Detailed Index of full Research Study: https://www.qyresearch.com/index/detail/1531346/global-malignant-mesothelioma-market

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Malignant Mesotheliomain these regions, from 2012 to 2022 (forecast), covering

Please Check below Chapters to display the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026].

There are 15 Chapters to display the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026].

Request for customization in Report and get it within 24 hours in your inbox: https://www.qyresearch.com/customize-request/form/1531346/global-malignant-mesothelioma-market

Table of Contents:

Chapter 1, to describe Definition, Specifications and Classification of Malignant Mesothelioma, Applications of Malignant Mesothelioma, Market Segment by Regions;

Chapter 2, To analyse the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Malignant Mesothelioma, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma ), Sales Analysis (AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma ), Sales Price Analysis (AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma );

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Malignant Mesothelioma Segment Market Analysis;

Chapter 7 and 8, to analyse the Malignant Mesothelioma Segment Market Analysis Major Manufacturers Analysis of Malignant Mesothelioma;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyse the Consumers Analysis of Malignant Mesothelioma;

Chapter 12, to describe Malignant Mesothelioma Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Malignant Mesothelioma sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read more from the original source:

Malignant Mesothelioma Market Emerging Trends, Global Demand and Business Opportunities 2020 to 2026 - 3rd Watch News

Immunotherapy Combination Proving Effective for Peritoneal Mesothelioma – Mesothelioma Guide

Posted on by

Most clinical trials experimenting with novel treatments focus on pleural mesothelioma, due to the higher incidence rates and poorer prognosis. Peritoneal mesothelioma often gets little attention.

One study combining two mesothelioma immunotherapy drugs is the anomaly to that truth.

Researchers from the MD Anderson Cancer Center in Houston, Texas, are analyzing the effects of atezolizumab and bevacizumab. Atezolizumab is an anti-PD-L1 drug, and bevacizumab is an anti-VEGF treatment.

Together they are called AtezoBev, and they showed promising results in a recent phase 2 clinical trial.

If you want to learn more about peritoneal mesothelioma treatment options, reach out to our medical staff. Our registered nurse, Jenna Campagna, can provide insight into the best methods for treating your individual diagnosis. Email her at jenna@mesotheliomaguide.com.

The standard treatment for peritoneal mesothelioma is cytoreduction with heated intraperitoneal chemotherapy (HIPEC). According to numerous studies, this approach can lead to survival times of between three and five years.

However, mesothelioma recurrence is frequent due to the makeup of the disease. Microscopic tumors fill the peritoneum, which is the small membrane covering the abdominal cavity, along with the abdominal cavity itself. Removing all of them during surgery is challenging.

Additionally, some patients might not be eligible for cytoreduction with HIPEC. Their cancer may resist traditional chemotherapy, which is typical for mesothelioma. Any treatment that may reduce tumor size prior to surgery or extend life for non-surgical patients should be investigated.

The atezolizumab and bevacizumab study included many types of cancers, including both peritoneal mesothelioma and pleural mesothelioma. It involved 160 patients, of which 20 had peritoneal mesothelioma. Patients received both atezolizumab and bevacizumab for 60 minutes once every three weeks, so long as the disease did not progress.

The American Society of Clinical Oncology analyzed the effectiveness of AtezoBev just among those 20 participants with peritoneal mesothelioma. Seven of the 20 (35%) experienced at least a minimal reduction in tumor size, which surpasses the original goal of just 11%.

Long-term follow-ups showed substantial benefits of AtezoBev:

Atezolizumab and bevacizumab work in distinctly different ways, but they have the same goal: mesothelioma cell death.

Atezolizumab prevents a connection that helps mesothelioma cells survive. These infected cells have a protein called PD-L1, which can subdue the bodys T-cells. These disease-fighting cells have the protein PD-1. When the two protein receptors link, the T-cells are inhibited from accurately assessing mesothelioma cells as dangerous.

Atezolizumab breaks this link and acts as a wall between the receptors. Its presence allows the T-cells to recognize mesothelioma cells as dangerous.

Bevacizumab, the generic name for the brand drug Avastin, subdues another mesothelioma protein called VEGF (vascular endothelial growth factor). This protein stimulates the creation of new blood vessels, a process called angiogenesis.

All cells, even cancerous ones, need to receive oxygen and nutrients to survive. Making new blood vessels is how mesothelioma tumors grow and spread through the body. Bevacizumab blocks this protein and can prevent mesothelioma cells from receiving oxygen and nutrients.

Show Sources & Author

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

Go here to see the original:

Immunotherapy Combination Proving Effective for Peritoneal Mesothelioma - Mesothelioma Guide

Scientists at Nainital-based ARIES shed new light on evolution of stars – The Tribune India

Posted on by

Vijay Mohan

Tribune News Service

Chandigarh, June 21

Astronomers at the Aryabhatta Research Institute of Observational Sciences (ARIES), Nanital, have found that stars of varied ages can co-exist in open clusters.

This challenges earlier understanding that all stars in an open cluster have the same age.

Open star clusters are a system of stars bound by gravity in which stars are born from the same molecular clouds. All the stars in a cluster follow the evolutionary sequence as per their initial masses at the time of formation of these stars. Open clusters are also important in probing the formation and evolution of the Milky Way galaxy as they are distributed throughout the galactic disk.

Scientists at ARIES measured the light emitted from three poorly studied open clusters, NGC-381, NGC-2360 and Berkeley-68 using the 1.3-m telescope situated in the Himalayas for studying the evolution of stars in these clusters. They found two different stellar evolutionary sequences in the cluster NGC-2360, which has been observed in very few open clusters in the Milky Way until now.

The team at ARIES, an autonomous institute under the Department of Science and Technology, observed thousands of stars in the three aforementioned clusters. The clusters are found to be relatively older, having ages between 446 Million years to 1,778 million years.

Other than the stellar evolution, the researchers also studied the dynamical evolution of these clusters for the first time. The mass distribution of stars belonging to the clusters has shown the preferential distribution of massive stars in the inner part of the clusters while low mass stars are found towards outer region of the clusters.

Scientists believe that some of the very low mass stars have in fact, left their parent clusters and may be roaming as a free star like our own Sun.

The study, recently published in the Monthly Notices of the Royal Astronomical Society, a leading journal in the field of astronomy and astrophysics published by Oxford University Press, United Kingdom, has lent important insight about the stellar and dynamical evolution of these clusters.

According to a statement issued by the Ministry of Science and Technology today, the scientists are further aiming to do an in-depth analysis of many more open star clusters in the near future using observational facilities available at ARIES along with the supplementary data provided by other space missions.

Original post:

Scientists at Nainital-based ARIES shed new light on evolution of stars - The Tribune India

Behind Joe Bidens Evolution on L.G.B.T.Q. Rights – The New York Times

Posted on by

If we established purity tests for elected officials, nobody would pass, said Emily Hecht-McGowan, who served as director for L.G.B.T.Q. equality at the Biden Foundation, a nonprofit group, until it was disbanded in 2019 when he began his presidential run. If we keep holding up our elected officials to these purity tests, we will never grow us a nation.

Mr. Griffin, the political consultant, said he was not bothered by the Defense of Marriage Act vote that, he noted, was 25, 26 years ago, when I was 19 years old and still in the closet.

Joe Biden has had 25 years since then to establish his own record and legacy, he said. I do not think that anyone can define Joe Biden by a vote 25 years ago when he has literally spent more than a decade championing L.G.B.T.Q. rights.

From the first weeks after the riots at the Stonewall Inn and the start of the modern-day gay rights movement, L.G.B.T.Q. leaders called for gay men and lesbians to come out. The explicit strategy was that increased visibility as family members, co-workers, civic leaders, celebrities would lead to more acceptance by the general public. One of Mr. Bidens grandchildren identifies as L.G.B.T.Q., an aide said.

Ms. McBride said that Mr. Biden grieved with her after her husband died at the age of 28; Mr. Biden had just lost his own son. He has officiated at two gay weddings, including in 2017 when Henry R. Muoz III, who was then the Democratic National Committees finance chairman, married his husband at Mr. Bidens home at the time in Northern Virginia.

He let me work alongside of him to push people in the administration on marriage equality, and then he married me, Mr. Muoz said.

The moment that elevated Mr. Bidens standing among gay and lesbian activists was his appearance on NBCs Meet the Press as vice president in 2012 when, in response to a question, he said he supported same-sex marriage. His response, which aides said was not calculated or planned, blindsided the White House and Mr. Obama, who had not yet staked out that position.

Continued here:

Behind Joe Bidens Evolution on L.G.B.T.Q. Rights - The New York Times

From Will Truman to Pray Tell: The evolution of TV’s queer leading men – NBC News

Posted on by

In 2001, Eric McCormack made history by winning the lead comedy actor Emmy for portraying a gay man on Will & Grace. Back then, the challenge was reflecting the gay experience as accurately as his co-star Debra Messings plotlines as a straight character in the NBC sitcom about two best friends.

We needed to show that the most accurate way to represent those two relationships was that they were always equal which, probably, they werent in the old days, McCormack says. It was easier to have handsome guys come on and date Deb Messing. Mine were handled with a lot more attention and a lot of being careful.

Today, as McCormack is eligible for a final nomination as the titular Will, his character is joined by a new class. The race includes Ben Platt, who portrays sexually fluid teenager-turned-early 20s politician Payton Hobart in Netflixs The Politician; Matt Bomers Jamie Burns, a man whose intimate connection with an old friend brings about carnage in Season 3 of USAs The Sinner; and Billy Porters Pray Tell in Pose, an HIV-positive ballroom emcee who got to explore a romance in the second season of the FX drama. The list of characters reflecting different facets of the queer experience and the fact that Platt, Bomer and Porter are all openly gay (McCormack is straight) shows how far TV has come since Will was standing more or less alone.

Porter, last years lead drama actor Emmy winner, has seen the shows storytelling grow even more complex in its second season. In addition to performing an intimate love scene, Porter was also a part of a story about the re-emergence of trauma from parental abuse. This allowed the actor to draw from personal experience.

Ive been waiting for this moment, Porter says. Ive been living for this moment to be able to tell my story. And as dark and as rich as the story is, I have a firsthand connection to it. I reached back to my memories and, every moment, just tried to share those with the world.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

That potential of creating art in part by drawing upon experience, and converting the tragic into catharsis is what queer actors taking on the spotlight allows.

We are at the forefront of telling our own narrative, says Porter, whose early career was marked by demands to play stereotypical roles when he was offered parts at all. Its not at the hands of other people who are outside the community anymore. Its so dreamy I just feel so blessed to have lived long enough to see this day.

Matt Bomers storyline on The Sinner provides less uplift than creepiness, but reflects the possibilities available beyond whats easily categorizable.

It was very important for Derek [Simonds, the shows creator] that it not be about a gay relationship, but about two men who had achieved this profound sense of intimacy where they had a shared sexual history, Bomer says. Its transcended that and become a romance with a philosophy and a sort of rage against society at large.

Just as his character exists beyond the nameable Bomer describes the season as Strangers on a Train mixed with Jekyll and Hyde mixed with Macbeth as interpreted by Patricia Highsmith so too does the actor see his own sexuality as existing somewhat apart from the character. (He played opposite Chris Messina, who is straight.)

What tends to be what I am hired for is to have chemistry, but I dont think its because of my comfort with my sexuality, he says. A lot of it just depends on the actors you get to work with and how open they are to come to set and drop the ego and play together and create something new.

All of which might have been too tangled for TV when Will & Grace was on the air in its first run in the 1990s and which made it a nostalgic throwback in its three victory-lap seasons. It knew its limitations: To do a really big, special episode of Will & Grace about the trans experience would have been taking on too much, McCormack says. But what we can do is show two very different gay men finding happiness, being in committed relationships, having a child.

While Will & Grace was built for a different TV moment one before characters on The Politician, Pose and The Sinner could probe queer life a bit more deeply and was a comedy besides, McCormack sees in its final seasons a depiction of Will that was as flawed and gratifyingly so as his three friends.

He wasnt on some sort of pedestal, McCormack says. Were all people, and were all growing.

So, too, is the medium, allowing for more complication in the lives of characters that existed in very different forms a generation before.

Follow NBC Out on Twitter, Facebook & Instagram

See more here:

From Will Truman to Pray Tell: The evolution of TV's queer leading men - NBC News

Norway’s Salmon Evolution names new CEO of land-based project – Undercurrent News

Posted on by

Land-based farming operation Salmon Evolution has chosen to stick withHakon Berg as its CEO, it announced.

Berg was first appointed CFO of the company in November 2019, and since March 2020 has held the role of acting CEO, when Odd Tore Finnoy stepped down.

Berg has "industrial and financial experience and expertise after many years of working with various industrial companies, and background from leadership in strategy and business development", his firm said.

Before joining Salmon Evolution, he was chairman of the board at Pure Norwegian Seafood, according to his LinkedIn profile.

"It is the combination of being the first to travel a full-scale industrial adventure of this magnitude in Norway, and my passion and experience in the seafood sector, which are the biggest driving forces and generates enthusiasm in me," Berg said.

He said he was confident the eventual 36,000 metric ton salmon farm -- likely one of Europes largest land-based facilities, when completed -- was going to solve several aquaculture issues, including sea lice, disease control, and sludge management.

"Controlled onshore production also opens up new circular opportunities, which in turn will create technology development, jobs, and resource reuse," he added.

Salmon Evolution chairman, Tore Tonseth, said the company would be "expanding the organization further in line with our needs", now that it had its CEO in place and had begun the first stages of construction.

The board of Salmon Evolution. From left: Glen Bradley, Kristofer Reiten, chairman Tore Tonseth, Peder Stette, Frode Kjolas

Read more from the original source:

Norway's Salmon Evolution names new CEO of land-based project - Undercurrent News

BMW Group unveils new logo in India: Brief evolution of BMW logos since 1917 – The Financial Express

Posted on by

BMW Group today introduced its new brand and corporate identity with its new logo and the rollout of its first communication campaign in India called Just Cant Wait. The BMW, BMW i and BMW M communication logos have been reworked with a new logotype. The Group says that the new brand logo delivers on the expectations and visual style of today and is better suited for the digital age. The #JustCantWait campaign is aimed at reflecting the brands customer-centricity and positivity.

BMW has always cherished its relationship with its esteemed customers and has introduced innovative products and value-added services. The new brand design and logo stand for openness and clarity. It symbolises the brands significance and relevance for mobility and driving pleasure in the future, Arlindo Teixeira, acting President, BMW Group India said.

BMW Group India has transformed itself to better serve its existing and new customers needs. With innovative services such as BMW Contactless Experience, BMW Easy Start Plan, BMW Advanced Hygiene Packages and Aftersales service packages, the brand stands true to its promise of offering Sheer Driving Pleasure to customers at all times, he added.

The new logo is much simpler in comparison to the previous one which was three-dimensional. BMW says that the pared-down and two-dimensional design conveys openness and clarity, adding that the change reflects BMWs transition from centering purely on the automotive world to being about technology and connections.

A brief history of BMW logos

The companys origin dates back to 1913 when it specialised in aircraft engines and was called Rapp Motorenwerke. The logo was changed to the first edition of the white & blue logo weve been used to seeing when the company was renamed Bayerische Motoren Werke or BMW in July 1917.

BMW entered the motorcycle market in 1923 with the R32. Its first car was a licensed copy of Austin Seven but by the early 1930s, BMW was producing cars developed in-house and that was also when in 1933 the logo was tweaked with thicker lettering and lines.

Also read:BMW India launches service & maintenance packages: 10-year service, unlimited repair mileage & more

BMW kept the 1933 logo for 20 years before changing it in 1953 bringing it closer to the one we grew up seeing with white lettering on black. This was updated 10 years later to a crisper but still a 2D logo in 1963. The 3D logo was introduced in 1997 and used until 2020. The new logo is back to 2D, is flatter, simpler and loses the dark background signifying transparency.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds,calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

View original post here:

BMW Group unveils new logo in India: Brief evolution of BMW logos since 1917 - The Financial Express

UAE Securities And Commodities Authority Hosts Webinar On The Evolution Of Supervisory Technology For Arab Regulators In Collaboration With Arab…

Posted on by

As part of its efforts to promote supervision over the securities sector in the country, the Securities and Commodities Authority (SCA), in collaboration with the Arab Federation of Exchanges (AFE), hosted a joint webinar on the evolution of supervisory technology, or SupTech, for Arab regulators. The webinar, titled Evolution of Supervisory Technology for Capital Markets, was held on June 15, using Microsoft Teams.

Its purpose was to share and exchange international experiences on supervisory technology. Participants in the webinar included representatives from financial market institutions, relevant stakeholders, economic and financial policymakers, in addition to representatives from supervisory and regulatory authorities and international organizations. An elite group of speakers, experts, and specialists in this field participated in the webinar sessions and discussions.

Items on the agenda included welcoming remarks by H.E. Dr. Obaid Al Zaabi,SCAs CEO, Vice Chair of the board of the International Organization of Securities Commissions (IOSCO), and Chair ofIOSCOs Growth and Emerging Markets Committee (GEMC). Richard Cutress delivered a presentation that provided an overview of supervisory technology and presented the perspective of the Financial Conduct Authority (FCA) of the UK.

The webinar included a panel discussion titled Adoption of SupTech and Lessons for Arab Regulators led by Varun Mittal, EY Global Emerging Markets Fintech Leader, and moderated by Mirna Sleiman, Founder and CEO of Fintech Galaxy. It featured panelists, including Narjes Farookh Jamal, Chief Operating Officer at Bahrain Bourse, and Sherif Samy, Chairman of the EgyptianFinTechAssociation and Former Chairman of the Financial Regulatory Authority.

The webinar was concluded with a keynote speech by Rami El Dokany, AFEs Secretary General, while the closing remarks were delivered by Lara Abdulmalak, Unlock Blockchains Editor-in-Chief.

Go here to read the rest:

UAE Securities And Commodities Authority Hosts Webinar On The Evolution Of Supervisory Technology For Arab Regulators In Collaboration With Arab...

The Whirlwind Path of Human Evolution – The Wire

Posted on by

Art showing stencilled hands (mostly left) in the Cueva de las Manos caves, Argentina, is dated between 11,000-7,000 BC. Photo: Mariano/Wikimedia Commons, CC BY-SA 3.0.

Any story that begins with the words 14 billion years ago is bound to be epic, and Transcendence: How Humans Evolved Through Fire, Language, Beauty, and Time, by Gaia Vince, is no exception. In the first chapter alone, Vince, an award-winning science writer and broadcaster based in London, covers the Big Bang, evolution, photosynthesis, the extinction of the dinosaurs, climate change and the presence of our early primate ancestors on the African savannah. Its a whirlwind and its only the beginning.

By the books conclusion, Vince has taken readers on a journey encompassing tens of thousands of years of human evolution that shows how our exceptional species has reset our relationship with nature and transformed into a new creature from our hypercooperative mass of humanity: we are becoming a superorganism. Vince calls it Homo omnis.

Whether you enjoy this kind of epic treatment of human history might depend on whether you like authors such as Jared Diamond, Stephen Pinker, Bill Bryson, and Yuval Noah Harari, who all write in a similar style: approachable, smart, and very ambitious. (Bryson got there first but nearly all of these authors books could have been called A Short History of Nearly Everything) Transcendence is most comparable to Hararis 2014 blockbuster Sapiens: both offer a sweeping account of human existence beginning with our origin as a species and ending with the idea that our species is becoming something post-human.

Unlike Harari, who focuses on a series of revolutions from the cognitive to the scientific, Vince chooses to highlight more nebulous and even poetic turning points in human evolution like beauty and time. We exist as the result of what she calls an evolutionary triad of genes, environment, and culture, and are now agents of our own transformation. She defines Homo omnis as a species that has transcended our evolutionary purpose to advance our genes for our cultural purpose, which is to be self-determining. Today, we are organisms with options: We can edit our genomes, choose the embryos of our offspring, prolong our lifespans, and maybe one day defeat death itself.

Vince takes care to deftly transition between one subject and another, bringing the reader along as she moves from topics like Wikipedia to cultural evolution to altruism to the neocortex to gossip to the survival of genes to monotheistic religion, as she does in the chapter called Telling. She argues early on that new collaborations between scientific fields, and in particular between the natural and social sciences, has allowed us to look at ourselves with new eyes and recognise the deep links that run through our biology, culture, and environment.

Likewise, Vince assembles the threads of these different disciplines and weaves them together to create moments of revelation for readers. She is uniquely talented in this respect, capable of presenting an impressive breadth of research from palaeoarchaeology to genetics to anthropology. In one of the best chapters, Story, she gives a rich and compelling account of Australian Aboriginal storytelling and the culturally universal strategy of the brain using story as a means to organise information and make it more memorable. Stories are a powerful survival adaptation, writes Vince, because they dont just allow us to travel back in time with our memories, they also allow us to mentally explore different future scenarios without expending time and energy.

Vince offers readers a vertiginous perspective of our existence on the planet. The cumulative effect seems intended to create awe and wonder in the reader, and inspire them to take seriously the responsibility of being an extraordinary species capable of directing our own destiny. But such an approach doesnt leave much room for nuance, and there are many instances when Vince presents readers with statements that would seem to merit greater skepticism, such as when she writes that In the United States, southerners are, as a group, more friendly and polite than northerners, who are often more brusque and ruder. Or, that more intelligent people tend to have fewer children; perhaps intelligence is being diluted in the gene pool.

Should we really accept without any discussion that people who live in cities are more inventive, or that the number of friends we have is determined by our genes? Other assertions seem intended to knock us over with profundity but end up feeling like platitudes. While animals are driven by biological urges to find food and mate, humans are also motivated by meaning and purpose, Vince writes. Or, We are all creatures of time.

In the end, Vinces provocative assertion that we are becoming a new species and the implications for our future become somewhat vague. She writes that human cultural evolution involves peaks and troughs, and that while there are reasons for pessimism and despair about the fate of our species today, its mostly a problem of perspective. Once we recognise and embrace our shared humanity, according to Vince, we can achieve a good, liveable Anthropocene. Perhaps. The lack of specificity regarding how our species will transcend the serious problems she enumerates (tribalism, individual self-interest, partisanship, fascism, war, violence, environmental catastrophe) feels like a letdown after such an intellectually voracious book.

Its worth asking why there is such a public appetite for science books written from a God-like vantage point at this time. Why do we seek out authors who try to explain everything? Is there security in the sense that someone out there can offer a coherent narrative that makes sense of where we come from and where we are going? Unfortunately, such authoritative, sweeping narratives often leave out what makes science so interesting in the first place: not just the certainties but the unknowns. Transcendence never lets us in on the process or methodologies by which studies come to their conclusions. Readers arent given a sense of the evolution of ideas or debates within scientific disciplines, or the individual scientists behind these ideas and what might drive them to do their research. We are never shown that just as science gives us answers, it also exposes the mysteries of our existence.

M.R. OConnor, a 2016-17 Knight Science Journalism fellow at MIT, writes about the politics and ethics of science, technology and conservation. She is the author of Resurrection Science: Conservation, De-Extinction and the Precarious Future of Wild Things and Wayfinding: The Science and Mystery of How Humans Navigate the Earth.

This article was originally published on Undark. Read the original article.

Visit link:

The Whirlwind Path of Human Evolution - The Wire

Revolution or evolution: has the moment for retail robotics arrived? – eDelivery

Posted on by

Recent weeks have seen automation and robotics start-ups netting new funding from investors, in a sign that retailers may be embracing automation in the wake of the coronavirus disruption.

Locus Robotics, a warehouse robotics company which counts DHL and Boots amongst its customers, netted $40 million in its latest funding round. The funding round, led by funds Zebra Ventures and Scale Venture Partners, brings Locus Robotics total funding to over $105 million.

Logistics robotics company Geek+, which offers robots for services such as cleaning and goods-to-picking, announced last week (18 June) that it had netted $200 million in its most recent funding round.

This has come as major retailers have adopted the technology, with Superdry deploying robots in warehouses in Europe while Gap has introduced them in the US.

Nigel Lahiri, sales director for EMEA at GreyOrange, a robotics company which counts Zalando amongst its customers, says that the pandemic has accelerated adoption of robotics in the logistics space. He highlights predictions that ecommerce will come to take up 40% of total retail (in the US),

Retailers understand that the acceleration [to ecommerce] is going to cause supply chain challenges.

He cites the hugely higher returns rates in online retail compared to physical as well as the generally lower margins available in ecommerce.

Retailers appetite for large-scale capital investments may be dampened by uncertainty about the economy in the wake of the Covid-19 shut-down. This will mean that retailers may deploy robots on a service model, paying a monthly fee rather than gutting their warehouses and buying robots in bulk.

Mark Thomson, director of retail at Zebra Technologies, whose investment arm led the recent funding round into Locus Robotics, says: Retailers dont particularly want to own the hardware why should they own robots? They want that service which robots are providing and the efficiency.

When youre dealing with a service level agreement from the provider you have a much more regular and ongoing conversation rather than a sales or transactional one.

He describes the adoption as an evolutionary rather than revolutionary process.

Its difficult to justify a huge structural investment in CapEx to rekit out, redesign or invest in brand new ones.

With its investment in Locus, Zebra Ventures is backing the cobot model, where robots are installed alongside human workers.

He says that while robots lack the dexterity of humans and cannot easily take over the actual picking and packing process without significant investment, they can take over routine, labour-intensive tasks.

One of these, which Locus specialises in, is robots walking the items from storage over to where they are picked, consolidated and packed.

This improves pick rate per hour without significant changes, making staff much more efficient.

Look at what you already have and look how you can optimise what is already in there, is how Thomson summarises the approach.

Zebra Technologies itself launched its SmartSight solution in January, an automated unit which can move around stores and automate certain processes there, such as making sure products are in the right place and have labels.

The fact that Covid-19 has led to retailers needing to implement social distancing within warehouses only makes the investment case for robots stronger in Thomsons view.

However, Thomson doesnt expect human workforces to disappear far from it.

Staff are not going away weve listened to a number of big retailers who say staff will become more expensive. Theyve actually increased the rates of pay because staff are critical to the customer experience. But they are not great at delivering customer experience if theyre doing these mundane, monotonous, labour-intensive tasks which you can do with automation.

Considering the uncertain economic climate and retailers caution about new technology, we shouldnt expect to see robots everywhere overnight. But as Thomson says, an evolution is taking place to a more hybrid model.

Image: Locus Robotics

Read more:

Revolution or evolution: has the moment for retail robotics arrived? - eDelivery

Healthcare Nanotechnology Market Evolution of Key Players That Will Change Industry: Amgen, Teva Pharmaceuticals, Abbott – Jewish Life News

Posted on by

Healthcare Nanotechnology Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2027. A Healthcare Nanotechnology market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

This Healthcare Nanotechnology market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

RequestSample PDF of Healthcare Nanotechnology Market Report https://www.worldwidemarketreports.com/sample/256063

Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen are some of the major organizations dominating the global market.

(*Note: Other Players Can be Added per Request)

Key players in the Healthcare Nanotechnology market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Healthcare Nanotechnology market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

The report also makes some important suggestions for the new Healthcare Nanotechnology market project before evaluating its feasibility. Overall, this report covers Healthcare Nanotechnology market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

This report includes market size estimates of value (million US $) and volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Healthcare Nanotechnology market, estimating the size of various other submarkets in the overall market. Major players in the market were identified through secondary studies, and market share was determined through primary and secondary studies. All ratio sharing, splitting and analysis were determined using the secondary source and the identified primary source.

What Healthcare Nanotechnology Market report offers:

Regions Covered in This Report

Complete knowledge of the Healthcare Nanotechnology market is based on the latest industry news, opportunities and trends in the expected region. The Healthcare Nanotechnology market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Healthcare Nanotechnology Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Visit link:

Healthcare Nanotechnology Market Evolution of Key Players That Will Change Industry: Amgen, Teva Pharmaceuticals, Abbott - Jewish Life News

The First Gene on Earth May Have Been a Hybrid – Scientific American

Posted on by

DNA and RNA, the two major modern forms of genetic code underpinning all of earthly biology, could have coexisted in strict pairings on our planet before life arose here, scientists in England, Scotland and Poland say. Using a hydrogen cyanidebased chemical system intended to mimic conditions in Earths early history, the researchers made four bases, the molecular letters of the genetic alphabet. Strung together, these bases form gene sequences that cells translate into proteins. But surprisingly, the team found that of the four bases their experiments consistently made, two were in a form found in DNA, whereas the other two were of a kind seen in RNA.

The study, published in Nature and conducted by John Sutherland of the Medical Research Council Laboratory of Molecular Biology in Cambridge, England, and his colleagues, further undermines the so-called RNA world hypothesis. This idea, long one of the most prominent in origins-of-life research, posits that RNA formed the basis of Earths biosphere long before DNA and other molecules important to life emerged. Yet to date, scant evidence has been found of chemical pathways to make the RNA-exclusive system that rigid versions of the idea adopt or that could lead to DNA. People have tended to think of RNA as the parent of DNA, Sutherland says. This [paper] suggests that they are molecular siblings.

Other scientists who were not involved with the study question the plausibility of the conditions used in this hydrogen cyanide-based route, however. Frances Westall, director of the exobiology group at the French National Center for Scientific Researchs Center for Molecular Biophysics in Orlans, notes that forming the bases requires very specific conditions. Mixtures would need to dry out and be exposed to ultraviolet lighttwo hurdles most easily surmounted on dry land, which was in short supply during our planets ocean-covered early days more than four billion years ago. These conditions certainly existed on the early Earth, Westall says. They would not have been that common because there was not that much exposed landmass. Although she adds that the study is clever and not completely impossible, she concludes that there are other, better hypotheses as to locations for the emergence of life and prebiotic molecules.

Arguments about plausibility have plagued the chemistry-based quest to understand lifes beginnings on Earth since the early 1950s, when American researchers Stanley Miller and Harold Urey performed a landmark experiment. The pair simulated the effects of lightning in the early Earths atmosphere and ocean by triggering electrical discharges in flasks containing hydrogen, water, ammonia and methane. Although their experiment famously produced sizable organic molecules vital for biochemistry, for decades other researchers have debated the plausibility of its conditions. Nevertheless, Miller and Ureys work showed that it was relatively simple to make important substances, such as the amino acids that link up to form proteins that perform myriad functions within living cells. Of particular relevance to origins-of-life studies, proteins can act as catalysts, enhancing and speeding up other chemical reactions that would otherwise be too slow or inefficient to plausibly occur. But proteins are not the only possible catalysts behind the rise of life on Earth.

In work that would ultimately net the 1989 Nobel Prize in Chemistry, molecular biologist Sidney Altman and biochemist Thomas Cech found that RNAlong considered merely an intermediate carrier of genetic information that is subservient to DNAcan also behave as a catalyst. The RNA world hypothesis suggests that such molecules could self-replicate, enabling early evolution before the existence of DNA and proteins. The idea, however, was an overzealous, overenthusiastic response to a brilliant discovery, Sutherland says.

That response might have come partly because, to a naive chemist, it looks easy to leap from RNA to DNA. To create the long chains we often see coiled up into the DNAs iconic double helix, the bases are first connected to a backbone of sugar molecules. These combinations make up nucleosides: deoxyribonucleotides in DNA and ribonucleosides in RNAwhich, unlike its DNA cousin, forms a single helix. The nucleosides do not use table sugar, or sucrose, but rather ribose in RNA and deoxyribose in DNA (the different sugars give each material its first initial). The distinction between the two sugar types is tiny: just one oxygen and one hydrogen atom. Yet that difference is enough for DNA and RNA to have distinct biological roles. And biochemically removing the atoms is far harder than simply erasing the letters representing them in a notebook.

Another flaw in the RNA world idea has been the difficulty of making ribose in the conditions that probably existed on the early Earthand to then connect it to a base. Sutherland and his colleagues therefore sought more likely ways to make ribose sugars and ribonucleosides. One of their most promising approaches relied on two gases thought to have been relatively abundant in the planets early atmosphere: hydrogen sulfide and hydrogen cyanide. When dissolved in water, bathed in ultraviolet light and subjected to cycles of drying, these simple compounds have produced many more complex molecules. They include amino acids and glycerol, the backbones of fatty molecules that can form cells outer wall.

Sutherland took this approach a step further last year. Working with Ramanarayanan Krishnamurthys team at the Scripps Research Institute in La Jolla, Calif., he and his colleagues showed that the ribonucleosides cytidine and uridine could be transformed into deoxyribose and the nucleoside and deoxyadenosine. Nowprimarily via the efforts of team members Jianfeng Xu and Vclav Chmela, both then at the Laboratory of Molecular Biologythe researchers have made even more progress. They mixed some of the intermediate molecules from the teams previous studies with salts such as sodium nitrite and magnesium chloride that could have been prevalent on the primordial Earth, then subjected them to acidic conditions and heat, respectively. Through these steps, the scientists found two possible routes to add a fourth base, the less common nucleoside inosine, to their preexisting collection. The addition was enough to make a four-letter genetic alphabet in which each base in a strand would exclusively pair with one of the other three letters in a second strand That base-pairing complementarity is how modern RNA and DNA works. But in the experiment, two letters came from RNA, and two came from DNA.

The arrangement suggests that the chemistry to make RNA and DNA isnt as different as people have thought, Sutherland says. People have tended to think of RNA coming before DNA and somehow then being taken over. This, to me, is suggesting that its possible that you could have had an RNA-DNA hybrid, which could then give rise to the two separate molecules. Sutherlands team has not yet assembled the individual nucleosides and ribonucleosides into longer chains, however. Doing so is important, because showing that hybrid strands can really form and bind to a partner strand is crucial for moving the idea beyond speculation.

This is a key issue for Nicholas Hud, an origins-of-life researcher at the Georgia Institute of Technology, who was not involved in the study. He calls it an excellent compilation of organic chemistry research on water-based nucleoside synthesis. But Hud is not convinced that the paper resolves whether these nucleosides actually arose before living creatures. His own research suggests amino acids could have linked up to carry information and act as a catalyst before RNA. Hud thinks evolution would then have gradually produced the current genetic system over long stretches of geologic time. If a molecule looks very difficult, from a chemical perspective, to make, yet it functions exquisitely in biology, then its probably the case that it has been evolved over time, he says. For the same reasons, he is also skeptical about the RNA world hypothesis.

Furthermore, Hud sees the new studys reliance on rigid incremental steps, each performed in strict order and under carefully controlled conditions, as a significant weakness. If the order of the steps changed or certain products were not isolated, Sutherland and his colleagues would have made much less of the substances they are interested in, Hud says. That caveat reduces the chances of the scenario unfolding in the chaotic environs of the early Earth.

Sutherland admits that, absent a time machine to travel back to lifes true origins on our planet, plausibility is everything in this rarefied field of research. Even so, he firmly backs his teams work on establishing chemical routes to lifes building blocks. There are many, many fingers pointing at hydrogen cyanide, Sutherland asserts. Does it prove that it all happened from hydrogen cyanide? It doesnt prove it. But its good enough for me.

Go here to read the rest:

The First Gene on Earth May Have Been a Hybrid - Scientific American

Lost 8 Billion Light Years of Universe Evolution Revealed by Gravitational Waves – SciTechDaily

Posted on by

Artistic impression of the background hum of gravitational waves permeating the Universe. Credit: Carl Knox, OzGrav/Swinburne University of Technology

Every year, 2 million black hole mergers are missed Australian scientists work out how to detect them, revealing a lost 8 billion light-years of Universe evolution.

Last year, the Advanced LIGO-VIRGO gravitational-wave detector network recorded data from 35 merging black holes and neutron stars. A great result but what did they miss? According to Dr. Rory Smith from the ARC Centre of Excellence in Gravitational Wave Discovery at Monash University in Australia its likely there are another 2 million gravitational wave events from merging black holes, a pair of merging black holes every 200 seconds and a pair of merging neutron stars every 15 seconds that scientists are not picking up.

Dr. Smith and his colleagues, also at Monash University, have developed a method to detect the presence of these weak or background events that to date have gone unnoticed, without having to detect each one individually. The method which is currently being test driven by the LIGO community means that we may be able to look more than 8 billion light-years further than we are currently observing, Dr. Smith said.

This will give us a snapshot of what the early universe looked like while providing insights into the evolution of the universe.

The paper, recently published in the Royal Astronomical Society journal, details how researchers will measure the properties of a background of gravitational waves from the millions of unresolved black hole mergers.

Artistic impression of the background hum of gravitational waves permeating the Universe. Credit: Carl Knox, OzGrav/Swinburne University of Technology

Binary black hole mergers release huge amounts of energy in the form of gravitational waves and are now routinely being detected by the Advanced LIGO-Virgo detector network. According to co-author, Eric Thrane from OzGrav-Monash, these gravitational waves generated by individual binary mergers carry information about spacetime and nuclear matter in the most extreme environments in the Universe. Individual observations of gravitational waves trace the evolution of stars, star clusters, and galaxies, he said.

By piecing together information from many merger events, we can begin to understand the environments in which stars live and evolve, and what causes their eventual fate as black holes. The further away we see the gravitational waves from these mergers, the younger the Universe was when they formed. We can trace the evolution of stars and galaxies throughout cosmic time, back to when the Universe was a fraction of its current age.

The researchers measure population properties of binary black hole mergers, such as the distribution of black hole masses. The vast majority of compact binary mergers produce gravitational waves that are too weak to yield unambiguous detections so vast amounts of information is currently missed by our observatories.

Moreover, inferences made about the black hole population may be susceptible to a selection bias due to the fact that we only see a handful of the loudest, most nearby systems. Selection bias means we might only be getting a snapshot of black holes, rather than the full picture, Dr. Smith warned.

The analysis developed by Smith and Thrane is being tested using real world observations from the LIGO-VIRGO detectors with the program expected to be fully operational within a few years, according to Dr. Smith.

Reference: Inferring the population properties of binary black holes from unresolved gravitational waves by Rory J E Smith, Colm Talbot, Francisco Hernandez Vivanco and Eric Thrane, 10 June 2020, Royal Astronomical Society.DOI: 10.1093/mnras/staa1642

Read this article:

Lost 8 Billion Light Years of Universe Evolution Revealed by Gravitational Waves - SciTechDaily